Sarcoma — Soblidotin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma
Citation(s)
A Phase II Study of Intravenous TZT-1027, Administered Weekly Times Two, Every Three Weeks, to Patients With Advanced or Metastatic Soft Tissue Sarcomas (STS) With Prior Exposure to Anthracycline-Based Chemotherapy